Climate Change Data

UCB

Climate Impact & Sustainability Data (2016, 2017, 2020, 2020-01 to 2020-06, 2021-01 to 2021-06, 2023)

Reporting Period: 2016

Environmental Metrics

Scope 3 Emissions:54,651 tons CO2e
Renewable Energy Share:80%
Total Energy Consumption:854,906 GJ
Water Consumption:704,310 m³
Waste Generated:8,712 tons

ESG Focus Areas

  • Responsible and ethical business conduct
  • Building an agile organization
  • Environmental stewardship and sustainability
  • Providing access to epilepsy care in resource-poor countries
  • Employee engagement

Environmental Achievements

  • Overall energy consumption decreased by 25%
  • Overall scope-1 and scope-2 CO2 emissions were reduced by 40%
  • Water consumption at UCB facilities decreased by 12%
  • Waste generated at UCB facilities decreased by 11%
  • 97% of waste was recovered

Social Achievements

  • Invested €15.9 million in training and development
  • Launched several initiatives to improve access to epilepsy care in resource-poor countries
  • 87% participation rate in UCB Voices employee engagement survey
  • €4.25 million spent in community sponsorships and charitable donations

Governance Achievements

  • 89% of colleagues completed Code of Conduct training
  • No significant risks related to human rights, anti-corruption, or anti-bribery identified
  • Three complaints received for deviation to industry voluntary codes regarding good promotional practices, with appropriate preventative actions identified

Climate Goals & Targets

Medium-term Goals:
  • Carbon neutral by 2030

Environmental Challenges

  • Changes in healthcare systems and increased pressure
  • Increasing environmental footprint upstream and downstream of operations
  • Data limitations due to new information system implementation and changes in reporting scope
Mitigation Strategies
  • Implementing Patient Value Strategy
  • Better understanding of environmental footprint across the value chain
  • Improved data validation and consolidation processes

Supply Chain Management

Responsible Procurement
  • Process for selection and engagement of suppliers, contractors, and agents to ensure adherence to human rights, anti-corruption, anti-bribery, and no child labor policies

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: GRI G4

Third-party Assurance: PricewaterhouseCoopers (PwC)

UN Sustainable Development Goals

  • SDG 3: Good Health and Well-being
  • SDG 4: Quality Education
  • SDG 5: Gender Equality
  • SDG 8: Decent Work and Economic Growth
  • SDG 9: Industry, Innovation and Infrastructure
  • SDG 13: Climate Action
  • SDG 17: Partnerships for the Goals

UCB's engagement in various initiatives linked to the SDGs

Awards & Recognition

  • London Stock Exchange’s FTSE4Good Index
  • ECPI
  • Corporate Knights
  • First prize of the EFPIA Patient Think Tank

Reporting Period: 2017

Environmental Metrics

Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:54987 tons
Renewable Energy Share:92%
Total Energy Consumption:771 GJ
Water Consumption:663,359 m3
Waste Generated:7090 tons
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Environmental
  • Social and employee matters
  • Human rights
  • Anti-corruption and bribery
  • Diversity & Inclusion

Environmental Achievements

  • Reached more than 92% green electricity (generated from renewable sources)
  • Reduced overall energy consumption by 5%
  • Reduced overall water consumption by 6%
  • Reduced waste generation by 19%
  • Recovered 91% of waste

Social Achievements

  • Launched or expanded patient support programs (UCB Cares® and UCB Assist)
  • 88% of employees consider UCB a socially responsible company
  • €7 million spent in community sponsorships and charitable donations
  • 19.5 hours of average training per employee
  • Improved employee engagement (85% participation rate in UCB Voices survey)

Governance Achievements

  • Implemented a company-wide due diligence process to assess human rights risks with new partners and suppliers
  • Completed mandatory training programs (Code of Conduct, Patient Safety Reporting, Anti-Bribery and Anti-Corruption)

Climate Goals & Targets

Long-term Goals:
  • Reduce GHG emissions by 70% by 2050
Medium-term Goals:
  • Reduce GHG emissions by 35% by 2030
  • Reduce water consumption by 20% by 2030
  • Reduce waste generation by 25% by 2030
  • Achieve carbon neutrality by 2030 for directly controlled operations
Short-term Goals:
  • Not disclosed

Environmental Challenges

  • Attracting, retaining, and engaging key leadership profiles and critical expertise in a competitive talent market
  • Ensuring adequate awareness of compliance requirements among workforce to mitigate reputational and regulatory risks
  • Maintaining a safe and healthy work environment
  • Addressing climate change regulatory requirements and their potential impact on compliance and value chain
  • Numeric safety imbalance in Evenity™ cardiovascular events
Mitigation Strategies
  • Robust annual human resources processes, competitive remuneration, employee performance reviews, continuous learning opportunities, periodic employee engagement surveys, and well-being initiatives
  • Specific training programs, systematic process controls of financial transactions, regular monitoring, integrity due diligence, and adherence to high standards by third parties
  • Implementation of certified Health & Safety management systems, periodic emergency exercises, regular inspections, and defining minimum global health & safety requirements
  • Stringent action plan to make operations carbon neutral by 2030, including reduction and compensation mechanisms
  • Comprehensive evaluation underway to understand the safety signal observed in Evenity™

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement
  • Strong centralized governance, risk management, and high-quality standards enforced by the Supply Chain Security Council

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Continuously changing regulatory requirements aimed at mitigating climate change
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: GRI G4 Sustainability Reporting Indicators

Certifications: ISO 14001 (Slough, Braine, Bulle, Zhuhai), OHSAS 18001 (Bulle, Slough, Zhuhai)

Third-party Assurance: PricewaterhouseCoopers (PwC)

UN Sustainable Development Goals

  • Not disclosed

The SDGs serve as a reference for the company.

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • London Stock Exchange's FTSE4Good Index
  • ECPI
  • Corporate Knights
  • EURORDIS Company Award
  • Best Ideas Award (UCB Iberia)
  • Best Company Award 2017 (UCB China)

Reporting Period: 2020

Environmental Metrics

Total Carbon Emissions:68,532 tCO2e/year (2020)
Scope 1 Emissions:30,647 tCO2e/year (2020)
Scope 2 Emissions:3,167 tCO2e/year (2020)
Scope 3 Emissions:34,718 tCO2e/year (2020)
Renewable Energy Share:95% (2020)
Total Energy Consumption:Not disclosed
Water Consumption:559,670 m3/year (2020)
Waste Generated:6,014 tons/year (2020)
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Scientific innovation
  • Access to medicines
  • Employees’ health, safety and wellbeing
  • Health of the planet
  • Diversity, equity, and inclusion
  • Ethical business practices

Environmental Achievements

  • Reduced CO2 emissions by 60% compared with 2015 benchmark
  • Reduced water withdrawal by 30% compared to 2015 benchmark
  • Reduced waste production by 38% compared to 2015 benchmark
  • Achieved 95% renewable energy share for electricity

Social Achievements

  • Positively impacted over 3.5 million patients' lives in 2020
  • Launched UCB Community Health Fund
  • Evolved health, safety and wellbeing (HSWB) ambition and delivery model, including the launch of a new HSWB index
  • Implemented various wellbeing and support programs for employees during the COVID-19 pandemic

Governance Achievements

  • Established a sustainability governance framework comprised of two bodies: Sustainability Governance Committee and External Sustainability Advisory Board
  • Completed Code of Conduct training for 8,034 employees (95% completion rate)
  • Completed ABAC training for 97% of employees
  • Maintained 100% compliance with health and safety of products regulations and voluntary codes

Climate Goals & Targets

Long-term Goals:
  • Reduce CO2 emissions and become carbon neutral for the operations we control directly by 2030
  • By 2025, lead in specific patient populations (partial onset/focal epileptic seizures, psoriatic arthritis, osteoporosis-related fractures, myasthenia gravis, and sub-populations of women of childbearing age)
Medium-term Goals:
  • Have 60% of the emissions created by our suppliers covered by SBTi-like targets by 2025
Short-term Goals:
  • Reduce water withdrawal by 20% by 2030
  • Reduce waste production by 25% by 2030

Environmental Challenges

  • Competition from biosimilars, generics and new drug classes
  • Intensity of successive product launches
  • Exchange rate volatility
  • Global pricing and access challenges
  • Cybersecurity/big data and artificial intelligence
  • Intellectual property
  • Impact of COVID-19 pandemic
Mitigation Strategies
  • Investing in superior overall value propositions in target patient populations; diversifying portfolio
  • Matching capabilities and reallocating resources and talents in an agile way
  • Hedging anticipated foreign currency cash flows
  • Actively engaging in collaboration with payor and industry associations
  • Multifaceted cybersecurity and data management strategy
  • Proactively aware of the competitive landscape around our programs; actively defending key patents
  • Implementing safety measures & wellbeing programs; continued supply of medicines; financial assistance for patients; contribution to COVID-19 research

Supply Chain Management

Supplier Audits: 100 suppliers assessed on sustainability performance (2020)

Responsible Procurement
  • Suppliers Code of Conduct

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Climate change, regulatory requirements, transition to low carbon economy
Opportunities
  • Development of energy-efficient products

Reporting Standards

Frameworks Used: GRI Standards

Certifications: ISO 14001, OHSAS 18001

Third-party Assurance: Third-party assurance provider (unspecified)

UN Sustainable Development Goals

  • SDG 3 (Good Health and Well-being)
  • SDG 13 (Climate Action)
  • SDG 17 (Partnerships for the Goals)

The report details how UCB's initiatives contribute to these goals.

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • European Carton Excellence Gold Award

Reporting Period: 2020-01 to 2020-06

Environmental Metrics

Social Achievements

  • Ensuring employee safety and financial support during the COVID-19 pandemic.
  • Providing targeted financial support and in-kind donations to local communities.
  • Giving extended payment terms to some vendors.

Climate Goals & Targets

Environmental Challenges

  • Impact of the COVID-19 pandemic on clinical studies (pause in new patient recruitment and postponement of new study starts).
Mitigation Strategies
  • Restarted clinical study recruitment and new study starts at sites meeting restart criteria.
  • Closely monitoring the impact of COVID-19 on ongoing clinical trials and implementing necessary changes.
  • Not applying for public support measures.
  • Not planning renegotiation of major contracts.

Supply Chain Management

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: IAS 34

Reporting Period: 2021-01 to 2021-06

Environmental Metrics

Climate Goals & Targets

Environmental Challenges

  • Impact of COVID-19 pandemic on staff, patients, partners, and communities.
Mitigation Strategies
  • Prioritizing assistance to employees, patients, and communities; implementing measures to protect health and ensure business critical activities; monitoring the impact of COVID-19 on clinical trials and implementing changes as necessary; leveraging multi-sourcing for key materials in its global supply chain to mitigate the impact of supply disruptions.

Supply Chain Management

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: IFRS

Reporting Period: 2023

Environmental Metrics

ESG Focus Areas

  • Human Rights
  • Sustainability
  • Ethical Business Conduct

Social Achievements

  • Commitment to creating a diverse, equitable and inclusive work environment for employees.
  • Commitment to fair practices and safe working conditions.
  • Respect for employee rights (unionization, living wage, reasonable working hours).

Governance Achievements

  • Establishment of a Human Rights Policy defining commitments, roles, responsibilities, and guiding principles.
  • Implementation of a grievance mechanism for reporting complaints and addressing adverse human rights impacts.
  • Strict non-retaliation policy to protect employees raising concerns or reporting misconduct.

Climate Goals & Targets

Medium-term Goals:
  • By 2030, all people who need our medicines in countries where we operate have access to them in a manner that is viable for patients, society, and UCB.

Environmental Challenges

  • Potential adverse human rights impacts in all parts of the business and supply chain.
Mitigation Strategies
  • Commitment to mitigating negative impacts and addressing potential adverse impacts.
  • Compliance with applicable laws and internationally recognized human rights principles.
  • Due diligence processes to identify and address priority human rights issues.
  • Supplier Code of Conduct to drive environmental sustainability and respect for human rights.

Supply Chain Management

Responsible Procurement
  • Supplier Code of Conduct

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: UN Global Compact, UN Guiding Principles on Business and Human Rights